U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Fri Jun 25 21:27:52 UTC 2021
Edited
by admin
on Fri Jun 25 21:27:52 UTC 2021
Protein Type RECEPTOR
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
UN0FN8L6YG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EGFR L861Q
Common Name English
EPIDERMAL GROWTH FACTOR RECEPTOR L861Q
Common Name English
ERBB L861Q
Common Name English
Code System Code Type Description
FDA UNII
UN0FN8L6YG
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
From To
1_7 1_34
1_133 1_163
1_166 1_175
1_170 1_183
1_191 1_199
1_195 1_207
1_208 1_216
1_212 1_224
1_227 1_236
1_240 1_267
1_271 1_283
1_287 1_302
1_305 1_309
1_313 1_338
1_446 1_475
1_482 1_491
1_486 1_499
1_502 1_511
1_515 1_531
1_534 1_547
1_538 1_555
1_558 1_567
1_571 1_593
1_596 1_604
1_600 1_612
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_32
N 1_49
N 1_104
N 1_151
N 1_172
N 1_328
N 1_337
N 1_389
N 1_420
N 1_504
N 1_544
N 1_579
N 1_599
Related Record Type Details
INHIBITOR -> TARGET
Uncommon EGFR mutations, including L861Q, G719X, and/or S768I
NON-INHIBITOR->OFF-TARGET
Overall survival (OS) was significantly shorter among patients with uncommon EGFR mutations (G719X or L861Q) com-pared with OS of those with common EGFR mutations (12 versus 28.4 months; p = 0.002). In the gefitinib group (n = 114), patients with uncommon EGFR mutations had a significantly shorter OS (11.9 versus 29.3 months; p < 0.001). By contrast, OS was similar between patients with uncommon mutations and those with common mutations in the carboplatin-paclitaxel group (n = 111; 22.8 versus 28 months; p = 0.358)
INHIBITOR -> TARGET
a case of successful treatment of a patient aged >80?years with lung adenocarcinoma positive for the uncommon EGFR L861Q mutation with low?dose afatinib. An 83?year?old woman presented with cough and dyspnea. A chest computed tomography (CT) scan revealed tumors in the left upper lobe, left pleural effusion, and multiple lung metastases in both lungs. The patient was diagnosed with lung adenocarcinoma with an EGFR L861Q mutation based on cytological findings. The patient received 30?mg/day of afatinib and experienced no severe adverse events.
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL